고인혈증 치료 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Hyperphosphatemia Therapeutics Market size was valued at USD 1.46 Billion in 2024 and is poised to grow from USD 1.58 Billion in 2025 to USD 2.94 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

Hyperphosphatemia, characterized by elevated phosphate levels in the blood, predominantly affects dialysis patients with end-stage renal disease. Key therapeutics for managing this condition include phosphate binders that limit phosphorus absorption, such as calcium salts, sevelamer, lanthanum carbonate, magnesium-based, and iron-based binders. The prevalence of hyperphosphatemia is notably high among individuals with chronic kidney disease and cardiovascular disorders, contributing significantly to morbidity and mortality. The decline in renal function leads to the body's inability to excrete phosphate effectively, necessitating various therapy strategies aimed at phosphate control. Increasing diagnoses and the need for effective treatments are driving market growth, despite challenges in maintaining optimal phosphate levels during dialysis, which can hinder the overall market development for hyperphosphatemia therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hyperphosphatemia Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hyperphosphatemia Therapeutics Market Segments Analysis

Global Hyperphosphatemia Therapeutics Market is segmented by Drug Class, Distribution Channel and region. Based on Drug Class, the market is segmented into Sevelamer, Calcium-based Phosphate Binders, Lanthanum Carbonate, Iron-based Phosphate Binders, Non-Phosphate Binders and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hyperphosphatemia Therapeutics Market

The growing incidence of chronic kidney disease (CKD) worldwide significantly drives the expansion of the Global Hyperphosphatemia Therapeutics market. This rise in CKD cases has led to an increased number of individuals requiring dialysis, with many patients experiencing hyperphosphatemia as a common complication. A significant portion of dialysis patients relies on phosphate binders for effective management of this condition, underscoring the critical need for such therapeutics. As the prevalence of chronic renal disease continues to escalate, the demand for effective treatments to address hyperphosphatemia is expected to surge, further bolstering market growth in this sector.

Restraints in the Global Hyperphosphatemia Therapeutics Market

A significant factor hindering the growth of the Global Hyperphosphatemia Therapeutics market is the low adherence to treatment among dialysis patients, primarily due to the extensive number of medications they are required to take. For many dialysis patients, managing their health involves consuming 10 to 12 different medications daily, with a substantial portion relying on phosphate binders that often come with adverse effects such as gastrointestinal issues. This overwhelming pill burden leads to increased noncompliance, as many patients struggle to manage their medication regimen effectively. Consequently, such challenges contribute to a projected decline in the utilization of phosphate binders among chronic kidney disease patients, ultimately limiting the market's expansion.

Market Trends of the Global Hyperphosphatemia Therapeutics Market

The Global Hyperphosphatemia Therapeutics market is witnessing a significant shift towards the adoption of non-phosphate binders, driven by the challenges associated with managing phosphate levels in chronic kidney disease (CKD) patients undergoing dialysis. Traditional phosphate binders often present adverse side effects and have not effectively improved phosphate management, prompting researchers to innovate and refine treatment protocols. Novel therapies, like Tenapanor, which inhibits the hydrogen/sodium exchanger isoform 3 (NHE3), are gaining attention for their potential to enhance therapeutic options and outcomes. This transition indicates a broader trend toward more effective and safer treatments for hyperphosphatemia, reshaping the competitive landscape of the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Hyperphosphatemia Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Sevelamer
• Calcium-based Phosphate Binders
• Lanthanum Carbonate
• Iron-based Phosphate Binders
• Non-Phosphate Binders
• Others

Global Hyperphosphatemia Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Hyperphosphatemia Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ardelyx, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Unicycive Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Keryx Biopharmaceuticals, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vifor Pharma Management Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care AG & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations